Claims for Patent: 9,339,466

Summary for Patent: 9,339,466

Title:	Polymorphic forms of ST-246 and methods of preparation
Abstract:	Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Inventor(s):	Tyavanagimatt; Shanthakumar R. (Corvallis, OR), Stone; Melialani A. C. L. (Corvallis, OR), Weimers; William C. (Corvallis, OR), Nelson; Dylan (Portland, OR), Bolken; Tove' C. (Keizer, OR), Hruby; Dennis E. (Albany, OR), O'Neill; Michael H. (Painesville, OH), Sweetapple; Gary (Madison, OH), McCloughan; Kelley A. (South Haven, MI)
Assignee:	SIGA TECHNOLOGIES, INC. (Corvallis, OR)
Application Number:	13/069,813
Patent Claims:	1. A polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2.theta. of about 7.63, 10.04, 11.47, 14.73, 15.21, 15.47, 16.06, 16.67, 16.98, 18.93, 19.96, 20.52, 20.79, 22.80, 25.16, 26.53, 27.20, 27.60, 29.60, 30.23, 30.49, 30.68, 31.14, 33.65, 34.33, 35.29, 35.56, 36.30, 37.36, 38.42, 38.66 degrees. 2. An isolated polymorph according to claim 1 that is at least 70% free of other forms. 3. An isolated polymorph according to claim 1 that is at least 80% free of other forms. 4. An isolated polymorph according to claim 1 that is at least 90% free of other forms. 5. An isolated polymorph according to claim 1 that is at least 95% free of other forms. 6. An isolated polymorph according to claim 1 that is at least 99% free of other forms. 7. A pharmaceutical composition comprising the polymorph of claim 1 and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carriers, excipients, diluents, additives, fillers, lubricants and binders. 8. The pharmaceutical composition of claim 7, wherein the composition is formulated for oral administration. 9. A method of producing the polymorph Form I according to claim 1, comprising the steps of: a) dissolving ST-246 in at least one organic solvent and an amount of water to make a solution; b) cooling said solution to a temperature that causes the preferential crystallization of said ST-246 polymorphic Form I; and c) optionally drying the formed crystals of ST-246, wherein the at least one organic solvent is selected from the group consisting of isopropyl alcohol (TPA), ethyl acetate, ethanol, methanol, acetone, isopropyl acetate and tetrahydrofuran (THF). 10. The method of claim 9 further comprising adding seed crystals of polymorphic Form I ST-246 during step (b). 11. The method of claim 9, wherein an organic solvent is methanol or THF. 12. The method of claim 9, wherein said cooling step takes place over at least 15 minutes. 13. The method of claim 9, wherein said cooling step takes place over at least 2 hours. 14. The method of claim 9, wherein said cooling step takes place over at least 5 hours. 15. The method of claim 9, wherein the at least one organic solvent is ethyl acetate. 16. The method of claim 9, wherein the at least one organic solvent is isopropyl alcohol. 17. The method of claim 9, wherein the at least one organic solvent is ethyl acetate and the water content is about 40% by volume of total solvent volume. 18. The method of claim 9, wherein the at least one organic solvent is ethyl acetate and the water content is about 5% by volume of total solvent volume. 19. The method of claim 9, wherein the at least one organic solvent is ethyl acetate and the water content is about 3% by volume of total solvent volume. 20. The method of claim 9, wherein the at least one organic solvent is ethyl acetate and the water content is about 2% by volume of total solvent volume. 21. The method of claim 9, wherein the at least one organic solvent is isopropyl alcohol and the water content is about 5% by volume of total solvent volume.